Clinical news
Every clinical development we have covered, newest first.
1 dated clinical item. Most recent: Retatrutide reaches 30.3% weight loss in Phase 3 (2026-08-04).
All-in monthly cost at 10 mg
What this beat covers
Trial results and label changes for the molecules this site prices. This beat is deliberately narrow: we cover clinical developments where they bear on a purchasing decision, and we do not translate trial outcomes into claims about compounded preparations.
That distinction is the whole discipline of the beat. Evidence generated on an FDA-approved product does not transfer to a pharmacy preparation of the same molecule, and anyone citing a trial result to sell a compounded vial is borrowing credibility from a product they are not dispensing.
Stories in this category
How to read a dated item
Every story carries the date we recorded it and links to what we read. Nothing here is undated, because an undated claim about a market that reprices this often is not usable. Where an item concerns a price, the figure is repeated with its dose and its fee basis attached rather than left to be inferred from the headline.
If an item is wrong, it gets a correction with a date rather than a silent edit. The full log is at corrections, and it includes errors we found in our own work.
Open these rather than taking our word for it. Every one is a regulator, a trial registry, a label, an accreditor or the manufacturer.